2023
What role does adjuvant therapy play in the management of endometrial cancer?
Huang G, Tymon-Rosario J, Santin A. What role does adjuvant therapy play in the management of endometrial cancer? Expert Opinion On Pharmacotherapy 2023, 24: 7-10. PMID: 36594708, DOI: 10.1080/14656566.2022.2157207.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2020
Stage III uterine serous carcinoma: modern trends in multimodality treatment
Li JY, Young MR, Huang G, Litkouhi B, Santin A, Schwartz PE, Damast S. Stage III uterine serous carcinoma: modern trends in multimodality treatment. Journal Of Gynecologic Oncology 2020, 31: e53. PMID: 32266802, PMCID: PMC7286763, DOI: 10.3802/jgo.2020.31.e53.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBrachytherapyEndometrial NeoplasmsFemaleHumansHysterectomyMiddle AgedNeoplasm StagingRadiotherapy, AdjuvantRetrospective StudiesConceptsUterine serous carcinomaExternal beam RTVaginal brachytherapyOverall survivalHuman epidermal growth factor receptorModern treatment eraSentinel node samplingRegional nodal recurrenceKaplan-Meier estimatesLog-rank testCox proportional hazardsExternal beam radiotherapyEpidermal growth factor receptorERA treatmentGrowth factor receptorUSC patientsFree survivalNodal recurrenceTreatment eraMultimodality treatmentPatient characteristicsPerioperative periodRegional nodalSerous carcinomaNode sampling
2004
Current treatment options for endometrial cancer
Santin AD, Bellone S, O’Brien T, Pecorelli S, Cannon MJ, Roman JJ. Current treatment options for endometrial cancer. Expert Review Of Anticancer Therapy 2004, 4: 679-689. PMID: 15270671, DOI: 10.1586/14737140.4.4.679.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Agents, HormonalAntineoplastic Combined Chemotherapy ProtocolsCarboplatinCell DifferentiationCisplatinDoxorubicinEndometrial NeoplasmsFemaleHumansHysterectomyNeoplasm InvasivenessNeoplasm Recurrence, LocalOvariectomyPaclitaxelPrognosisRadiotherapy, AdjuvantReceptor, ErbB-2Risk FactorsSurvival AnalysisTrastuzumabConceptsEndometrial cancerMyometrial invasionStage I endometrial cancer patientsLow-toxicity regimenEndometrial cancer patientsLymph node dissectionRecurrent endometrial cancerTotal abdominal hysterectomyClear cell histologyCornerstone of treatmentPostoperative radiation therapyImportant prognostic factorCurrent treatment optionsCombination of cisplatinFemale genital tractAttractive therapeutic strategyMajority of casesType II receptorExtrapelvic recurrenceAbdominal hysterectomyNode dissectionPelvic radiotherapyPelvic recurrenceSystemic chemotherapyVaginal bleeding